OR WAIT 15 SECS
Unigen says that in the unpublished study, AmLexin supported exercise recovery and attenuated delayed onset muscle soreness (DOMS) post-exercise.
A joint-health ingredient combining Acacia catechu heartwood and Morus alba root bark extract, branded AmLexin, supported exercise recovery and attenuated delayed onset muscle soreness (DOMS) post-exercise in a new study, according to the ingredient’s supplier, Unigen (Seattle). Results from this study will be presented at Experimental Biology 2018 in San Diego, CA.
In the double-blind, placebo-controlled, clinical study, 26 subjects were given either 400 mg/day AmLexin or an identical dosage of a placebo. The study took place over nine total weeks, and included an eight-week running training program. Subjects continued supplementation with AmLexin for one week following a 13.1-mile half-marathon run.
According to Unigen, the researchers found that the group given the AmLexin joint-health ingredient exhibited significantly lower levels of muscle soreness after the nine-week study period than the placebo group. In addition, the firm says, the AmLexin group experienced lower levels of post-exercise discomfort than did the placebo group. Unigen says the researchers concluded that AmLexin may help to promote post-exercise recovery within just one to six days following exercise. This study is not yet published.
A press statement from the company noted that this study in athletes is the second clinical trial supporting AmLexin’s ability to help relieve discomfort and stiffness and to improve mobility in healthy adults. [Adding this, because for all I know that first study was just a regular joint-health study with no sports angle. It’s weird that they say this study shows improved mobility in healthy adults without talking about how that links to the reduction in muscle soreness in the study.] In the first published clinical study, it said, researchers found that supplementation with AmLexin resulted in a significant reduction of a urinary biomarker for cartilage breakdown. Specifically, it was shown to reduce the amount of glycosaminoglycan, a free radical generated by tissue wear and tear. Regan Miles, president, CEO, Unigen, commented on how the new study results add to the growing research supporting AmLexin’s joint- and muscle-health benefits.